Recent developments in federal cannabis policy center on the Drug Enforcement Administration's April 2026 final order, which moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective late April. This action followed a December 2025 executive order directing expedited review and replaces earlier proposed rulemaking. An administrative hearing now set to begin June 29, 2026, and conclude by July 15 will examine full rescheduling of all marijuana to Schedule III, with participants selected in advance and firm procedural deadlines in place. Traders monitor this compressed timeline, prior HHS scientific recommendations, and any intervening agency statements for signals on whether broader changes could finalize before mid-2026 deadlines or extend further.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено$758,572 Объем
30 июня
1%
31 декабря
24%
$758,572 Объем
30 июня
1%
31 декабря
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Открытие рынка: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent developments in federal cannabis policy center on the Drug Enforcement Administration's April 2026 final order, which moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective late April. This action followed a December 2025 executive order directing expedited review and replaces earlier proposed rulemaking. An administrative hearing now set to begin June 29, 2026, and conclude by July 15 will examine full rescheduling of all marijuana to Schedule III, with participants selected in advance and firm procedural deadlines in place. Traders monitor this compressed timeline, prior HHS scientific recommendations, and any intervening agency statements for signals on whether broader changes could finalize before mid-2026 deadlines or extend further.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы